ALGN Align Technology, Inc.

$170.50▼ -4.27% Healthcare Other Last sync: just now Syncing
Key Metrics & Fundamentals
Market Cap
$12.21B
P/E Ratio
30.0
Div Yield
–%
52W Range
122.00 - 208.31
% vs 50 MA
2.69%
% vs 200 MA
11.85%
RSI-14
58.9
MACD Histogram
+1.9000
Beta (1Y vs SPY)
1.61
Free Cash Flow
$120.26M
Gross Rev
$1.04B
Gross Profit
$736.59M
EBITDA
$259.77M
COGS
$303.50M
Operating Exp
$564.00M
Operating Income
$172.59M
EBIT
$172.59M
Pretax Income
$148.89M
Net Income
$112.77M
EPS (Diluted)
1.57
Price & Volume History
Volume (M)
Financial Overview - Income Statement Quarterly
AI Analysis
Generated May 28, 3:48 AM
Company Overview

Align Technology, Inc. is a global medical device company primarily known for its Invisalign clear aligner system, a leading alternative to traditional braces, and its iTero intraoral scanners. The company holds a dominant market position in the rapidly expanding digital orthodontics and restorative dentistry sectors, driven by continuous innovation and a strong global brand presence.

Bull Case
  • Align Technology maintains a significant market share in the growing clear aligner segment with its globally recognized Invisalign brand.
  • Substantial opportunities for growth exist in international markets, particularly in emerging economies with increasing demand for aesthetic dental solutions.
  • The company consistently invests in R&D, enhancing its aligner technology, digital treatment planning, and iTero scanner capabilities, driving product differentiation.
  • Increasing consumer awareness and demand for discreet orthodontic treatments among both adults and teenagers provide a strong long-term growth driver.
Bear Case
  • The clear aligner market faces increasing competition from both established players and new entrants, including direct-to-consumer models.
  • As a discretionary healthcare expense, demand for Invisalign treatments can be vulnerable to economic downturns and fluctuations in consumer disposable income.
  • The company operates in a highly regulated industry, facing potential challenges related to medical device approvals, intellectual property disputes, and evolving healthcare policies.
  • Despite recent price corrections, the P/E ratio of 27.4 may still reflect high growth expectations, which could be challenged by market saturation or slower adoption rates.
Recent Performance

ALGN has experienced a significant correction, trading 21.8% below its 52-week high, indicating recent bearish sentiment. While the stock is currently below its 50-day moving average, suggesting short-term downward momentum, it remains above its 200-day moving average, implying a more resilient long-term uptrend. The RSI of 43.2 indicates neutral momentum, not signaling extreme overbought or oversold conditions, but reflecting the recent price weakness.

AI-generated analysis is for informational purposes only and does not constitute financial advice.

Not Financial Advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making any investment decisions. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙